In this study, we show that PTK6 expression promotes growth of ER+ breast cancer cells even in the presence of tamoxifen, and PTK6 inhibition induces apoptosis of ER+ breast cancer cells, including those resistant to estrogen deprivation and ER-targeted therapies, including the ER degrader fulvestrant. The gene discussed is PTK6; the disease is breast cancer.